Skip to main content

What the label lists and what reports show

Adenosine side effects

Adenosine's FDA label: “Most common adverse reactions (incidence ≥ 10%) are: flushing; chest discomfort; shortness of breath; headache; throat, neck or jaw discomfort; gastrointestinal discomfort; …” FAERS holds 1,600 reports naming it through July 30, 2026; the reaction reported most often, leaving out the conditions it is used for, product-use terms and outcomes, is supraventricular tachycardia (98 reports).

  • Generic listed

Check it at the source: the adenosine FDA label on DailyMed (effective April 14, 2025, Meitheal Pharmaceuticals Inc.); the FDA FAERS public dashboard.

What does the label list?

From the label: adverse reactions

Most common adverse reactions (incidence ≥ 10%) are: flushing; chest discomfort; shortness of breath; headache; throat, neck or jaw discomfort; gastrointestinal discomfort; and dizziness ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Meitheal Pharmaceuticals, Inc.

A table the label prints in its adverse reactions section without a title; its column headings name the groups compared

Adverse ReactionsAdenosine N=1,421
Flushing44%
Chest discomfort40%
Dyspnea28%
Headache18%
Throat, neck or jaw discomfort15%
Gastrointestinal discomfort13%
Lightheadedness/dizziness12%
Upper extremity discomfort4%
ST segment depression3%
First-degree AV block3%
Second-degree AV block3%
Paresthesia2%
Hypotension2%
Nervousness2%
Arrhythmias1%

Rows and numbers as the label prints them, under its own column headings (the first rows of a longer table where it runs on). A reaction in a trial table is not necessarily caused by the medicine, and trials differ from everyday use.

From the label: adverse reactions, continued

The following adverse reactions are discussed in more detail in other sections of the prescribing information: Fatal Cardiac Arrest, Ventricular Arrhythmias, and Myocardial Infarction [see Warnings and Precautions ( 5.1 )] Sinoatrial and Atrioventricular Nodal Block [see Warnings and Precautions ( 5.2 )] Bronchoconstriction [see Warnings and Precautions ( 5.3 )] Hypotension [see Warnings and Precautions ( 5.4 )] Cerebrovascular Accident [see Warnings and Precautions ( 5.5 )] Seizures [see Warnings and Precautions ( 5.6 )] Hypersensitivity [see Warnings and Precautions ( 5.7 )] Atrial fibrillation [see Warnings and Precautions ( 5.8 )] Hypertension [see Warnings and Precautions ( 5.9 )] Most common adverse reactions (incidence ≥ 10%) are: flushing; chest discomfort; shortness of breath; headache; throat, neck or jaw discomfort; gastrointestinal discomfort; and dizziness ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Meitheal Pharmaceuticals, Inc. at 1-844-824-8426 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA drug label, Meitheal Pharmaceuticals Inc., effective April 14, 2025 (SPL set b6851256-6cef-4f23-8129-19bb64380cd5), via openFDA; the full label on DailyMed

What do FAERS reports show?

1,600 reports list adenosine among the medicines taken, each a report of something that happened, not proof the medicine caused it; 142 are coded as a death and 758 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is. Of the 19 reactions below, 11 are named by the same term (in US spelling) in the label's adverse reactions, warnings or patient leaflet; a reaction the label does not name may still be there under another word, and a report does not show that the medicine caused it.

Reports received each year

The 25 most reported reactions

  • Drug Ineffective (a use or a product term, not a reaction)341
  • Off Label Use (a use or a product term, not a reaction)106
  • Supraventricular Tachycardia98
  • Hypotension (named in the label)88
  • Cardiac Arrest (named in the label)79
  • Dyspnoea (named in the label)74
  • Pain70
  • Atrial Fibrillation (named in the label)66
  • Bradycardia (named in the label)63
  • Tachycardia (named in the label)62
  • Nausea (named in the label)57
  • Anxiety55
  • Drug Interaction (a use or a product term, not a reaction)54
  • Product Use In Unapproved Indication (a use or a product term, not a reaction)54
  • Dizziness (named in the label)49
  • Ventricular Tachycardia (named in the label)49
  • Pneumonia43
  • Bronchospasm (named in the label)41
  • Fatigue41
  • Drug Ineffective For Unapproved Indication (a use or a product term, not a reaction)37
  • Emotional Distress37
  • Hypertension (named in the label)37
  • Ventricular Fibrillation36
  • Maternal Exposure During Pregnancy (a use or a product term, not a reaction)35
  • Renal Failure34

Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026; reactions as MedDRA preferred terms

What next?

Adenosine: the full record
label, generics, price, shortages, recalls
Side effects hub
the most reported medicines and reactions